Hyperhidrosis

Candesant Biomedical announced positive results from its pilot study on the targeted alkali thermolysis patch, an investigational treatment for patients with axillary hyperhidrosis, according to a company press release.

The use of glycopyrronium cloth without occlusion for 30 minutes had the best results in treating palmar hyperhidrosis, according to results of a virtually conducted study.

Findings from a meta-analysis showed that abobotulinumtoxinA was safe and effective, with high patient satisfaction, in individuals with hyperhidrosis.

Journey Medical will acquire Qbrexza from Dermira, according to a press release.

Pediatric patients reported hyperhidrosis in multiple focal areas, with disease severity correlating with depression and anxiety, according to a poster at the Masters of Pediatric Dermatology meeting.

Treatment with sofpironium bromide gel reduced the severity of primary axillary hyperhidrosis in a cohort of pediatric patients, according to a poster presented at South Beach Symposium Medical Dermatology Summit.

Sofpironium bromide gel reduced hyperhidrosis with few adverse events in Japanese patients, according to findings from a phase 3 study presented at the American Academy of Dermatology virtual meeting.

Sofpironium bromide gel reduced hyperhidrosis severity and demonstrated an acceptable safety profile in a phase 2 study detailed in Journal of the American Academy of Dermatology.